Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd Market 2016 Share, Trend, Segmentation and Forecast to 2022

Monday, October 10, 2016 5:22
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Product Pipeline Review – 2016’, provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

 

Complete report details @ https://www.wiseguyreports.com/reports/649770-shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd-product-pipeline-review-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 
- The report provides overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Request a sample report @ https://www.wiseguyreports.com/sample-request/649770-shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd-product-pipeline-review-2016

Reasons to buy

- Evaluate Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline 
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 
- Identify potential new clients or partners in the target demographic 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/649770-shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd-product-pipeline-review-2016

Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 4 
List of Figures 4 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Snapshot 5 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Overview 5 
Key Information 5 
Key Facts 5 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Research and Development Overview 6 
Key Therapeutic Areas 6 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline Review 9 
Pipeline Products by Stage of Development 9 
Pipeline Products – Monotherapy 10 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline Products Glance 11 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Clinical Stage Pipeline Products 11 
Phase II Products/Combination Treatment Modalities 11 
Phase I Products/Combination Treatment Modalities 12 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Early Stage Pipeline Products 13 
IND/CTA Filed Products/Combination Treatment Modalities 13 
Preclinical Products/Combination Treatment Modalities 14 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Unknown Stage Pipeline Products 15 
Unknown Products/Combination Treatment Modalities 15 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Drug Profiles 16 
aminolevulinic acid hydrochloride 16 
Product Description 16 
Mechanism of Action 16 
R&D Progress 16 
Hitenercept 17 
Product Description 17 
Mechanism of Action 17 
R&D Progress 17 
Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis 18 
Product Description 18 
Mechanism of Action 18 
R&D Progress 18 
T-0001 19 
Product Description 19 
Mechanism of Action 19 
R&D Progress 19 
vincristine sulfate 20 
Product Description 20 
Mechanism of Action 20 
R&D Progress 20 
bevacizumab biosimilar 21 
Product Description 21 
Mechanism of Action 21 
R&D Progress 21 
Fderceptin 22 
Product Description 22 
Mechanism of Action 22 
R&D Progress 22 
Monoclonal Antibody Conjugate to Target CD30 for Solid Tumor 23 
Product Description 23 
Mechanism of Action 23 
R&D Progress 23 
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia 24 
Product Description 24 
Mechanism of Action 24 
R&D Progress 24 
Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis 25 
Product Description 25 
Mechanism of Action 25 
R&D Progress 25 
paclitaxel 26 
Product Description 26 
Mechanism of Action 26 
R&D Progress 26 
etanercept biosimilar 27 
Product Description 27 
Mechanism of Action 27 
R&D Progress 27 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline Analysis 28 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline Products by Target 28 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration 29 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline Products by Molecule Type 30 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline Products by Mechanism of Action 31 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Dormant Projects 32 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Discontinued Pipeline Products 33 
Discontinued Pipeline Product Profiles 33 
Nifeviroc 33 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Locations And Subsidiaries 34 
Head Office 34 
Other Locations & Subsidiaries 34 
Appendix 35 
Methodology 35 
Coverage 35 
Secondary Research 35 
Primary Research 35 
Expert Panel Validation 35 
Contact Us 35 
Disclaimer 36

List of Tables 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Information 5 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Facts 5 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline by Indication, 2016 8 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2016 9 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2016 10 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Phase II, 2016 11 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Phase I, 2016 12 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – IND/CTA Filed, 2016 13 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Preclinical, 2016 14 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Unknown, 2016 15 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline by Target, 2016 28 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline by Route of Administration, 2016 29 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline by Molecule Type, 2016 30 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 31 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Dormant Developmental Projects,2016 32 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. – Discontinued Pipeline Products, 2016 33 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Subsidiaries 34

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649770

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.